| Jul 16 |
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
|
| Jul 11 |
One VYNE Therapeutics Insider Raised Stake By 55% In Previous Year
|
| Jul 9 |
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
|
| Jun 26 |
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
|
| Jun 13 |
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
|
| Jun 5 |
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
|
